Ranbaxy Mulls Sale Of Lipitor Generic Rights If U.S. FDA Delays
This article was originally published in PharmAsia News
Ranbaxy Laboratories said a delay in U.S. approval of its generic version of Pfizer's best-selling anti-cholesterol Lipitor (atorvastatin) might cause it to sell rights to another firm
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.